Tags

Type your tag names separated by a space and hit enter

Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
ASAIO J. 2003 Jul-Aug; 49(4):430-4.AJ

Abstract

Low density lipoprotein (LDL) apheresis provides both structural and physiologic improvement to the vascular wall. The purpose of this study was to determine whether LDL pheresis alters levels of plasma matrix metalloproteinase-9 (MMP-9) and serum tissue inhibitor of matrix metalloproteinase-1 (TIMP-1). MMP-9 and TIMP-1 were measured in 30 healthy control subjects (Group A), 20 type 2 diabetic hemodialysis patients without obvious arteriosclerosis obliterans (ASO) (Group B), and 20 type 2 diabetic hemodialysis patients with ASO (Group C). Hemodialysis patients were dialyzed three times weekly with a bicarbonate dialysate. Twelve Group C patients underwent LDL apheresis once weekly for 10 weeks, and changes in plasma MMP-9 and serum TIMP-1 levels because of LDL apheresis were measured. LDL apheresis resulted in a significant decrease in total cholesterol and LDL cholesterol levels (p < 0.01). In addition, LDL apheresis improved clinical symptoms (including cold lower extremity, intermittent claudication, and leg pain) and diminished the size of ulcer/necrosis in all patients. Plasma MMP-9 levels were significantly higher in Group C (76.5 +/- 14.6 ng/ml) than in Group A (31.2 +/- 8.4 ng/ml, p < 0.001) or Group B (58.5 +/- 10.8 ng/ml, p < 0.05). Serum TIMP-1 levels were significantly higher in Group C (360.5 +/- 116.5 ng/ml) than in Group A (142.5 +/- 82.5 ng/ml, p < 0.001) or Group B (254.6 +/- 92.6 ng/ml, p < 0.05). Plasma MMP-9 and serum TIMP-1 levels decreased significantly after LDL apheresis (p < 0.05). However, these levels showed little change in the remaining eight Group C patients who did not undergo LDL apheresis. The data suggested that MMP-9 and TIMP-1 are associated with ASO and that LDL apheresis is effective in reducing plasma MMP-9 and TIMP-1 levels in type 2 diabetic hemodialysis patients with ASO.

Authors+Show Affiliations

Division of Nephrology, Department of Medicine, Misato Junshin Hospital, Saitama, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12918586

Citation

Nakamura, Tsukasa, et al. "Effects of Low-density Lipoprotein Apheresis On Plasma Matrix Metalloproteinase-9 and Serum Tissue Inhibitor of Metalloproteinase-1 Levels in Diabetic Hemodialysis Patients With Arteriosclerosis Obliterans." ASAIO Journal (American Society for Artificial Internal Organs : 1992), vol. 49, no. 4, 2003, pp. 430-4.
Nakamura T, Matsuda T, Suzuki Y, et al. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ASAIO J. 2003;49(4):430-4.
Nakamura, T., Matsuda, T., Suzuki, Y., Ueda, Y., & Koide, H. (2003). Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ASAIO Journal (American Society for Artificial Internal Organs : 1992), 49(4), 430-4.
Nakamura T, et al. Effects of Low-density Lipoprotein Apheresis On Plasma Matrix Metalloproteinase-9 and Serum Tissue Inhibitor of Metalloproteinase-1 Levels in Diabetic Hemodialysis Patients With Arteriosclerosis Obliterans. ASAIO J. 2003 Jul-Aug;49(4):430-4. PubMed PMID: 12918586.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. AU - Nakamura,Tsukasa, AU - Matsuda,Takaharu, AU - Suzuki,Yukiko, AU - Ueda,Yoshihiko, AU - Koide,Hikaru, PY - 2003/8/16/pubmed PY - 2003/12/9/medline PY - 2003/8/16/entrez SP - 430 EP - 4 JF - ASAIO journal (American Society for Artificial Internal Organs : 1992) JO - ASAIO J VL - 49 IS - 4 N2 - Low density lipoprotein (LDL) apheresis provides both structural and physiologic improvement to the vascular wall. The purpose of this study was to determine whether LDL pheresis alters levels of plasma matrix metalloproteinase-9 (MMP-9) and serum tissue inhibitor of matrix metalloproteinase-1 (TIMP-1). MMP-9 and TIMP-1 were measured in 30 healthy control subjects (Group A), 20 type 2 diabetic hemodialysis patients without obvious arteriosclerosis obliterans (ASO) (Group B), and 20 type 2 diabetic hemodialysis patients with ASO (Group C). Hemodialysis patients were dialyzed three times weekly with a bicarbonate dialysate. Twelve Group C patients underwent LDL apheresis once weekly for 10 weeks, and changes in plasma MMP-9 and serum TIMP-1 levels because of LDL apheresis were measured. LDL apheresis resulted in a significant decrease in total cholesterol and LDL cholesterol levels (p < 0.01). In addition, LDL apheresis improved clinical symptoms (including cold lower extremity, intermittent claudication, and leg pain) and diminished the size of ulcer/necrosis in all patients. Plasma MMP-9 levels were significantly higher in Group C (76.5 +/- 14.6 ng/ml) than in Group A (31.2 +/- 8.4 ng/ml, p < 0.001) or Group B (58.5 +/- 10.8 ng/ml, p < 0.05). Serum TIMP-1 levels were significantly higher in Group C (360.5 +/- 116.5 ng/ml) than in Group A (142.5 +/- 82.5 ng/ml, p < 0.001) or Group B (254.6 +/- 92.6 ng/ml, p < 0.05). Plasma MMP-9 and serum TIMP-1 levels decreased significantly after LDL apheresis (p < 0.05). However, these levels showed little change in the remaining eight Group C patients who did not undergo LDL apheresis. The data suggested that MMP-9 and TIMP-1 are associated with ASO and that LDL apheresis is effective in reducing plasma MMP-9 and TIMP-1 levels in type 2 diabetic hemodialysis patients with ASO. SN - 1058-2916 UR - https://www.unboundmedicine.com/medline/citation/12918586/Effects_of_low_density_lipoprotein_apheresis_on_plasma_matrix_metalloproteinase_9_and_serum_tissue_inhibitor_of_metalloproteinase_1_levels_in_diabetic_hemodialysis_patients_with_arteriosclerosis_obliterans_ L2 - https://Insights.ovid.com/pubmed?pmid=12918586 DB - PRIME DP - Unbound Medicine ER -